
Financing - May 27, 2014
Isofol raises SEK 38 million
The capital injection will be used for further clinical development of the company’s drug candidate. Modulfin is currently in phase I/II and is developed to increase the efficacy and decrease side effects during cancer treatments. It is based on a derivative of the B vitamine folic acid. At the moment, Modulfin is tested on cancer […]